Therapy News and Research

RSS

Too much salt and aldosterone leads to high blood pressure, tissue damage

Nearly 40 percent of the small adrenal tumors that cause big problems with high blood pressure share a genetic mutation that causes patients to retain too much sodium, researchers report.

31 May 2012

Researchers identify new peptide that can block fibrosis of the skin and lungs

A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today.

31 May 2012

Researchers look into value of adapted yoga for stroke rehabilitation

Researchers looking into the value of adapted yoga for stroke rehabilitation report that after an eight-week program, study participants demonstrated improved balance and flexibility, a stronger and faster gait, and increased strength and endurance.

31 May 2012

Skin transplant surgery safe and effective for patients with vitligo

Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

31 May 2012

Every Child Deserves a 5th Birthday weekly theme is PMTCT

"The Every Child Deserves a 5th Birthday theme for this week is prevention of mother-to-child transmission of HIV (PMTCT)," an e-mail alert from USAID reports, noting, "PMTCT provides HIV prevention, treatment, care, and support services for the whole family and is the most effective way to create an HIV-free generation."

31 May 2012

UCLA research projects aim to improve lives of children with serious illnesses

New hope for deadly pediatric brain tumors; opening the door to improved diagnosis and treatment of epilepsy in children; and advanced genetic testing to better understand the causes of autism and cancer in kids. These research projects are currently underway at Mattel Children's Hospital UCLA under the umbrella of the UCLA Children's Discovery and Innovation Institute (CDI), and aim to dramatically improve the lives of children with serious illnesses.

31 May 2012

ProCure Proton Therapy Center successfully treats first cancer patient

Bound Brook, N.J. resident Frank Mackinson became the first patient to complete treatment at the ProCure Proton Therapy Center in Somerset, N.J.— a milestone that was celebrated with family, friends and Mackinson's treatment team. The Somerset Center opened officially on March 20 (one month ahead of schedule), enabling Mackinson to begin treatment on March 28. Proton therapy is a precise form of radiation treatment for cancer without many of the short- and long-term side effects often experienced with standard X-ray radiation.

31 May 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

Kona Medical raises $30 million in Series C financing

Kona Medical, Inc. today announced it has raised $30 million in Series C financing to advance its novel hypertension therapy.

31 May 2012

Pharmspective releases ‘Molecular Diagnostics Insights in Oncology’

Pharmspective, LLC today announced the release of its second syndicated report – Molecular Diagnostics Insights in Oncology. This new extensive survey of over 400 oncologists characterizes the emerging molecular diagnostics landscape and the role and influence of specific assays in clinical management and therapy selection.

31 May 2012

Stiefel to acquire WBI-1001 licensing rights from Welichem

Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.

31 May 2012

Foundation Medicine introduces first pan-cancer genomic profile

Foundation Medicine announced today the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients' treatment options.

31 May 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

Study examines how SMIP-016 drug kills CLL cells

A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic leukemia. The finding could lead to more effective therapy for chronic lymphocytic leukemia (CLL), an as yet incurable cancer that occurs in more than 16,000 Americans annually.

31 May 2012

BHD launches Statin Induced Myopathy Genotype test

Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation.

31 May 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

Pfizer’s XALKORI now available in Canada

Pfizer Canada is pleased to announce that XALKORI (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).

31 May 2012